Two landmark studies from the University of Gothenburg have cracked open a mystery that has long puzzled researchers: why does weight loss from bariatric surgery protect women—but not men—from cancer? The answer lies in an elegant biological dance between insulin, genes, and gender, offering new hope for personalized cancer prevention.
The research, drawn from the Swedish Obese Subjects (SOS) Study, one of the world's most comprehensive long-term investigations of weight-loss surgery, tracked over 4,000 people with obesity for decades. What emerged from the data was striking: while substantial weight loss dramatically reduced cancer risk in women, men showed no such benefit. The pattern was strongest for female-specific cancers like breast and gynecological cancer, pointing to something uniquely protective happening in women's bodies after surgical weight loss.
The first study, published in PLOS Medicine, zeroed in on insulin as a likely culprit. Researchers discovered that the cancer-protective effect was most pronounced in women who had elevated insulin levels before surgery—suggesting that how the body processes glucose and manages metabolic hormones plays a central role in cancer risk. Insulin doesn't just regulate blood sugar; it influences cell growth and division, the very processes that can go awry in cancer. When weight loss brought insulin levels down, the cancer shield went up.
But the story became even more precise in the second study, published in Scientific Reports. Here, researchers examined whether genetic background could explain why some women benefited more than others. They focused on a common variant in the FTO gene—a stretch of DNA previously linked to higher BMI and increased breast cancer risk. The results were remarkable: women carrying this genetic variant experienced a 47% reduction in breast cancer risk after bariatric surgery, compared with those receiving standard obesity treatment. For women without the variant, no clear benefit emerged.
The protective effect strengthened dramatically when genetic and metabolic factors aligned. Women who carried the FTO gene variant and had high insulin levels at the study's start saw their breast cancer risk plummet by approximately 64% after surgery. This synergy—where biology meets genetics—suggests that the body's response to weight loss is deeply individual, shaped by inherited traits and metabolic signatures written long before surgery.
Kajsa Sjöholm, an associate professor at the University of Gothenburg, emphasized the significance: "Our results suggest that there are biological differences between individuals that affect how much cancer risk is reduced after weight loss. By understanding these differences, we will get closer to the mechanisms underlying the connection between obesity and cancer."
The implications extend beyond bariatric surgery. A new generation of highly effective weight-loss medications is rapidly transforming obesity treatment, raising the question: which patients will benefit most? These findings suggest the answer isn't one-size-fits-all. Instead, as Magdalena Taube, who led the studies, explains, the future points toward precision medicine—tailoring cancer prevention strategies to gender, metabolic health, and genetic background. Understanding which women carry the FTO variant, which have metabolic dysfunction, and which are most vulnerable could soon allow doctors to predict who needs the most aggressive interventions. The studies demonstrate that reducing cancer risk isn't simply about the number on the scale. It's about the intricate biology happening beneath the skin.